Submitted: 09 Jun 2019
Accepted: 23 Aug 2019
First published online: 09 Sep 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Renal Inj Prev. 2020;9(1): e04.
doi: 10.15171/jrip.2020.04
  Abstract View: 57
  PDF Download: 65

Original

The therapeutic efficnecy of ranolazine in comparison with conventional therapy in diabetic individuals with ischemic heart disease; a randomized clinical trial

Bahram Fariborz Farsad 1 ORCiD, Seyed Mostafa Alavi 1 * ORCiD, Golshid Ghorbanian 2, Fanak Fahimi 2, Zahra Ghaemmaghami 1, Ali Zahed Mehr 3, Hooman Bakhshandeh 1

1 Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
2 Clinical Pharmacy Department, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical & Research Center, Iran University of Medical Sciences, Tehran, Iran
*Corresponding author: Seyed Mostafa Alavi, Email: Email: mostafa.alavi@gmail.com

Article

Introduction: Patients with diabetes mellitus (DM) have higher risk of coronary artery disease (CAD) and angina than the general population.

Objectives: We sought to assess the impact of ranolazine as an antianginal agent to diminish hemoglobin A1c (Hb A1c) level in diabetic individuals under treatment with metformin and gliclazide.

Patients and Methods: This study was a randomized parallel-group clinical trial to compare the therapeutic effects of ranolazine versus conventional treatment in patients with concomitant T2DM and stable angina. TERISA (type 2 diabetes mellitus evaluation of ranolazine in subjects with chronic stable angina) was employed to assess the efficiency of ranolazine in lowering the frequency of angina attacks. The study was performed on diabetic patients with symptomatic angina under treatment with either sublingual nitroglycerin or up to two types of antianginal agents. The patients in the intervention group received 1000 mg ranolazine twice a day while patients in the control group were administrated with conventional treatment. Reduction in baseline Hb A1c level was determined at 4 and 8 weeks after the interventions.

Results: Ranolazine therapy resulted in up to 15% absolute reduction in Hb A1c level in diabetic patients who had baseline HbA1c level >7%. Ranolazine was more efficient in reducing Hb A1c in patients with poorly controlled disease (i.e. HbA1c>8%, P=0.017). Ranolazine did not affect the glycemic status of patients concomitantly treated with antidiabetic therapy (P=0.560).

Conclusion: Concurrent administration of ranolazine along with anti-diabetic treatments (i.e. metformin and gliclazide) was safe to reduce the level of HbA1c in patients with poorly controlled diabetes and stable angina.

Implication for health policy/practice/research/medical education:

Ranolazine can improve quality of life and exercise tolerance and reduce angina frequency. Ranolazine can also improve HbA1c level in individuals with concomitant type 2 diabetes mellitus and chronic stable angina without imposing any adverse effects on kidneys.

Please cite this paper as: Fariborz Farsad B, Alavi SM, Ghorbanian G, Fahimi F, Ghaemmaghami Z, Zahed Mehr A, Bakhshandeh H. The therapeutic efficnecy of ranolazine in comparison with conventional therapy in diabetic individuals with ischemic heart disease; a randomized clinical trial. J Renal Inj Prev. 2020; 9(1): e04. DOI: 10.15171/jrip.2020.04.

First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 57

Your browser does not support the canvas element.


PDF Downloaded: 65

Your browser does not support the canvas element.